Respironics closes Profile acquisition:
This article was originally published in Clinica
Executive Summary
Respironics, the Murrysville, Pennsylvania respiratory products maker, has completed the $46m acquisition of its UK distributor, Profile Therapeutics. A spokesperson for Profile said Respironics did not plan any redundancies or major changes at the Bognor Regis, Sussex-based firm, which has its own range of inhalation technologies. Existing management will continue to run the business, as a subsidiary of Respironics. Profile says becoming part of a large global group should help accelerate its R&D plans.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.